Evropska unija - slovenščina - EMA (European Medicines Agency)

amicus therapeutics europe limited - migalastat hydrochloride - fabryjeva bolezen - migalastat - galafold je indiciran za dolgotrajno zdravljenje odraslih in mladostnikov, starih 16 let in več, s potrjeno diagnozo fabryjeve bolezni (pomanjkanje α-galaktozidaze a) in ki imajo amenabilno mutacijo.

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - hepatitis c, kronični - antivirusi za sistemsko uporabo - victrelis je indicirano za zdravljenje kroničnega hepatitisa c (chc) genotip 1 okužbe, v kombinaciji z peginterferon alfa in ribavirin pri odraslih bolnikih z nadomestiti bolezen jeter, ki so predhodno nezdravljenih ali ki niso prejšnje zdravljenje.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

generics (uk) ltd. - karbidopa; levodopa; entakapon - filmsko obložena tableta - karbidopa 37,5 mg / 1 tableta  levodopa150 mg / 1 tableta  entakapon200 mg / 1 tableta; levodopa 150 mg / 1 tableta  entakapon200 mg / 1 tableta; entakapon 200 mg / 1 tableta - levodopa, zaviralec dekarboksilaze in zaviralec comt

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

generics (uk) ltd. - karbidopa; levodopa; entakapon - filmsko obložena tableta - karbidopa 37,5 mg / 1 tableta  levodopa150 mg / 1 tableta  entakapon200 mg / 1 tableta; levodopa 150 mg / 1 tableta  entakapon200 mg / 1 tableta; entakapon 200 mg / 1 tableta - levodopa, zaviralec dekarboksilaze in zaviralec comt

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - aripiprazol - schizophrenia; bipolar disorder - psiholeptiki - zdravilo aripiprazole je indicirano za zdravljenje shizofrenije pri odraslih in pri mladostnikih, starih 15 let ali več. aripiprazole soglasju je primerna za zdravljenje zmerno do hudo manične epizode v bipolarne motnje i bolezni in za preprečevanje novo manično epizodo pri odraslih, ki so imeli pretežno manične epizode in katerih manične epizode se odzvali na zdravljenje aripiprazole. aripiprazole soglasju je primerna za zdravljenje do 12 tednov, z zmerno do hudo manične epizode v bipolarne motnje i motnje pri mladostnikih, ki so stari 13 let in starejši.

Evropska unija - slovenščina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.